This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.
JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2018 FINANCIAL RESULTS
Hamilton, Bermuda – 04 March 2019 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced its 2018 fourth quarter and full year financial. The filing stated:
TotalRevenues Increased17% to$1.9Billion in 2018
GAAPDilutedEPSof$7.30;AdjustedDilutedEPSof$13.70
LaunchedVyxeosforAMLintheEUandInitiatedBroadDevelopmentProgramReceivedU.S.ApprovalofXyremforPediatricNarcolepsy
SubmittedtheMAAtoEMAforSolriamfetolinExcessiveDaytimeSleepinessinNarcolepsyandObstructiveSleepApnea
CompletedPatientEnrollmentinJZP-258Phase3StudyinNarcolepsyandInitiatedPatientEnrollmentinJZP-258Phase3StudyinIdiopathicHypersomnia
2019FullYearRevenueGuidanceof$2.05to$2.13Billion
DUBLIN, February 26, 2019 --JazzPharmaceuticalsplc (Nasdaq:JAZZ) todayannounced financialresultsforthefullyearand thefourth quarter of 2018 and provided financialguidance for 2019.
“Our evolution as a global biopharmaceutical companycontinued in 2018 as we delivered another year ofrecordrevenues and madesubstantial progress on keymilestones, including advancing multiple pre-clinical,early- and late-stage development programs. We also initiated abroad development program togenerate data forVyxeos in newAMLpatient populations and other hematologic malignancies,”saidBruceCozadd, chairmanand chiefexecutive officerof JazzPharmaceuticals.“In 2019, our strongfinancialposition and scalable operations provide afoundationforfurther growth as we focus on keyregulatoryapprovals, planned product launches, our development pipeline and multiple initiatives tomaximize our commercial portfolio.”
GAAPnet income for 2018 was $447.1 million, or$7.30 per diluted share,comparedto $487.8 million, or $7.96 per diluted share,for2017.GAAP net income forthefourth quarter of 2018 was $159.5 million,or $2.64 per diluted share,comparedto $232.2 million, or $3.79 per diluted share,forthe fourth quarterof 2017.2017 GAAPnet income, forthefullyearand thefourthquarter, included a net taxbenefit
of $148.8 million,or $2.43 per diluted share,relatedtoenactment of theU.S. Tax Cuts and JobsAct(U.S.TaxAct).
Adjustednet income for 2018 was $838.6 million, or$13.70 per diluted share,compared
to$676.7 million, or$11.04 per diluted share,for 2017.Adjustednet income forthefourth quarter of2018 was $220.0 million, or $3.64 per diluted share,comparedto $180.5 million, or $2.95 per dilutedshare,forthefourthquarter of 2017.Reconciliations of applicable GAAP reportedtonon-GAAP adjustedinformation are included at theend of thispress release.
The full press release can be found by using the following link:
Contacts:
Investors:
Kathee Littrell
VicePresident,InvestorRelationsJazzPharmaceuticals plc
Ireland,+353 1 634 7887
U.S.,+1650 496 2717
Media:
JacquelineKirby
VicePresident,CorporateAffairs &GovernmentRelationsJazzPharmaceuticals plc
Ireland,+3531 697 2141
U.S.,+1215 867 4910